Definitive Contract HHSN272201400056C

This federal contract award, valued at $10,517,896.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of California, San Diego (UCSD). The award is part of NIAID's Vaccine Adjuvant Discovery Program (VADP), which supports the identification and characterization of novel, effective, and safe vaccine adjuvants. The contract does not have a set-aside designation. UCSD will lead the research efforts, which will focus on four key areas: (1)...

This is a $9,807,060 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Chicago. The contract is for the Vaccine Adjuvant Discovery Program (VADP), which aims to evaluate and develop animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics. This contract is not set-aside and is a cost-type...

This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...

This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to The Leland Stanford Junior University (Stanford University), a private research institution. The $19,155,153 contract is for a 5-year research program to compare multiple vaccine adjuvants and comprehensively assess the immune responses they induce. The goal is to develop "immune fingerprints" of adjuvants using advanced...

This federal contract award was issued by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) to Immport Therapeutics, Inc., doing business as Antigen Discovery Inc. The $110,458.00 firm fixed price purchase order is for ADI Leptospirosis work, with a performance period ending August 18, 2020. Antigen Discovery is a biotechnology company that provides microarray products and services to support the CDC's disease detection and response efforts, including...

This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...

This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...

This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and...

This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS). The contract, valued at $196,994.14, is a delivery order for stability testing of CPG 7909, a vaccine adjuvant. The contract does not have a set-aside designation. ABL is a leading contract research and manufacturing organization that specializes in the development of gene...